• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Basic Materials·ASTEC.NS
Share

Astec LifeSciences Limited Stocks

₹ 572.55Last Updated 02.09.2026

Issuer Rating

3/7
Performance

Poor

Risk

Moderate

Recommendation

Sell

Market Cap

₹ 135.91M

₹ 572.55
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Astec LifeSciences Limited, together with its subsidiaries, manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India. The company provides triazole fungicides for use in field crops; foliar treatment for the control of scab, powdery mildew, shot-hole, blossom blight, and rust; seed treatment for the control of seed and soil-borne diseases in cotton and maize, as well as grains, such as barley, rice, and wheat; post-harvest drench; and food additive and wood preservative. It also provides herbicides, insecticides, and specialty chemical products. The company also exports its products. The company was incorporated in 1994 and is based in Mumbai, India. Astec LifeSciences Limited is a subsidiary of Godrej Agrovet Limited.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. Specifically, the stock is overvalued on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of ASTEC.NS is 633 and suggests 10.6% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommenda

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

04.09.2026 08:00

Volkswagen plans to cut 50,000 jobs. What does this mean for investors?

04.09.2026 07:30

"AI Consultant Riding the FOMO Wave": Burry Expects Palantir's Stock Price to Fall by a Factor of Four

04.09.2026 02:21

Revolut has received conditional approval for a license in the U.S. It will launch a bank in 2027

04.09.2026 01:14

S&P 500 Posts Best Monthly Gain, Financial Sector Hits New Record: Fed Statements Calm the Market

04.09.2026 00:40

OpenAI has launched a new AI model, GPT-6 Astra. The company calls it the smartest in the world

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026